title: Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest.
abstract: Honokiol (HNK), a naturally occurring biphenyl, possesses potent antineoplastic and antiangiogenic properties. We investigated the in vitro and in vivo activity of HNK against breast cancer. HNK exhibited potent anti-proliferative activity against breast cancer cell lines and enhanced the activity of other drugs used for the treatment of breast cancer. In vivo, HNK was highly effective against breast cancer in nude mice. We identified two different effects of HNK on breast cancer cells: cell cycle inhibition, observed at lower doses of HNK, and induction of apoptosis, observed at higher doses of the compound. Our data suggest that HNK is a systemically available, non-toxic inhibitor of breast cancer growth and should be examined for clinical applications.
authors.affiliation: Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA, USA. wolf-i@inter.net.il
authors.forename: Ido
authors.initials: I
authors.lastname: Wolf
authors.forename: James
authors.initials: J
authors.lastname: O'Kelly
authors.forename: Naoki
authors.initials: N
authors.lastname: Wakimoto
authors.forename: Anh
authors.initials: A
authors.lastname: Nguyen
authors.forename: Franck
authors.initials: F
authors.lastname: Amblard
authors.forename: Beth Y
authors.initials: BY
authors.lastname: Karlan
authors.forename: Jack L
authors.initials: JL
authors.lastname: Arbiser
authors.forename: H Phillip
authors.initials: HP
authors.lastname: Koeffler
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy*; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage; D066298:In Vitro Techniques; D017705:Lignans / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D017239:Paclitaxel / Q000008:administration & dosage; D013629:Tamoxifen / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077337:Vorinostat; D000498:Allyl Compounds; D010636:Phenols
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D001713:Biphenyl Compounds; D004317:Doxorubicin; D006877:Hydroxamic Acids; D017705:Lignans; D017239:Paclitaxel; D013629:Tamoxifen; D000077337:Vorinostat; C005499:honokiol; D000498:Allyl Compounds; D010636:Phenols; C016601:afimoxifene